Prescient Therapeutics Limited (ASX: PTX) is a clinical stage oncology company. It develops novel drugs which are used as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy treatments. The headquarter of the company is situated in South Melbourne, Australia and is being currently headed by Mr. Yatomi-Clarke Steven Lee – the CEO, MD, and Director.

Register Now

Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)

By clicking on submit, you agree to receive the aforesaid information & marketing offers as per our Privacy Policy.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK